Toward personalized medicine for intrahepatic cholangiocarcinoma: Pharmacogenomic stratification of patients

Paula Olaizola¹, Maria J Perugorria^{1

2

3}, Jesus M Banales^{1

2

3}

Affiliations

¹ Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
² National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
³ IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

Editorial

Paula Olaizola et al. Hepatology. 2018 Sep.

. 2018 Sep;68(3):811-814.

doi: 10.1002/hep.29830. Epub 2018 May 14.

Paula Olaizola¹, Maria J Perugorria^{1

2

3}, Jesus M Banales^{1

2

3}

¹ Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
² National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
³ IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.

No abstract available

Comment on

Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.
Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB. Nepal C, et al. Hepatology. 2018 Sep;68(3):949-963. doi: 10.1002/hep.29764. Epub 2018 Jun 12. Hepatology. 2018. PMID: 29278425 Free PMC article.

1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016;13:261-280.
1. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829-840.
1. Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015;47:1003-1010.
1. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:1021-1031.
1. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 2017;19:2878-2880.